Merck KGaA plans to phase out most animal testing in favor of new approach methodologies (NAMs) such as organs-on-a-chip and organoids over the next decade. The move aligns with a global regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results